B+
Bull case
20%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-07-22 · RankAlpha Sentiment Codex
IMNN
ImunonBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-07-22 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-07-22 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-22
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.3
Score
AI commentary
Primary-source tone is positive on Phase 2 efficacy, FDA alignment, and OVATION 3 enrollment, while recent coverage also highlights financing. Social, options, short-interest, employee-review, and analyst-revision evidence is unavailable, so this remains a low-coverage monitoring view rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-07-22
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystFinancing and cash-burn sensitivityHigh impact
The company reported a Q1 2026 net loss of $4.3 million and previously described a cost-reduction reorganization; the packet also contains an unconfirmed secondary report of a $10 million funding package. Financing terms and runway remain key near-term risks [#SEC-8K-2026-05-12].
2026-10-20eventOVATION 3 enrollment executionHigh impact
Management reported that Phase 3 OVATION 3 enrollment was ahead of plan, with enrollment expected to complete by Q1 2029. The FDA has reviewed and aligned with the protocol and stated path to BLA filing [#SEC-8K-2026-05-12].
2027-07-22catalystPhase 3 validation of IMNN-001High impact
The core upside case depends on confirming the Phase 2 OVATION 2 survival signal in the pivotal study. The company reported a final 14.7-month median overall-survival improvement, but registrational validation remains several years away and execution-dependent [#SEC-8K-2026-05-12][#SEC-8K-2026-03-31].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology